Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CAPR |
---|---|---|
09:32 ET | 396 | 3.33 |
09:51 ET | 400 | 3.35 |
09:55 ET | 100 | 3.35 |
09:57 ET | 250 | 3.3322 |
10:00 ET | 1792 | 3.34 |
10:04 ET | 100 | 3.35 |
10:06 ET | 100 | 3.35 |
10:08 ET | 100 | 3.35 |
10:18 ET | 100 | 3.44 |
10:22 ET | 300 | 3.48 |
10:24 ET | 5296 | 3.44 |
10:26 ET | 300 | 3.44 |
10:27 ET | 1000 | 3.35 |
10:29 ET | 3133 | 3.3101 |
10:31 ET | 810 | 3.44 |
10:33 ET | 5000 | 3.38 |
10:36 ET | 684 | 3.405 |
10:38 ET | 100 | 3.405 |
10:40 ET | 500 | 3.4223 |
10:49 ET | 200 | 3.42 |
10:54 ET | 200 | 3.42 |
10:58 ET | 11400 | 3.365 |
11:02 ET | 100 | 3.38 |
11:09 ET | 100 | 3.4 |
11:12 ET | 100 | 3.4 |
11:14 ET | 100 | 3.38 |
11:16 ET | 193 | 3.36 |
11:18 ET | 100 | 3.38 |
11:21 ET | 100 | 3.35 |
11:23 ET | 500 | 3.38 |
11:25 ET | 10516 | 3.42 |
11:27 ET | 100 | 3.44 |
11:39 ET | 165 | 3.44 |
11:41 ET | 300 | 3.435 |
11:43 ET | 300 | 3.435 |
11:48 ET | 100 | 3.46 |
11:50 ET | 200 | 3.44 |
11:54 ET | 8959 | 3.44 |
11:56 ET | 300 | 3.44 |
11:57 ET | 100 | 3.44 |
11:59 ET | 100 | 3.44 |
12:06 ET | 200 | 3.44 |
12:10 ET | 100 | 3.44 |
12:12 ET | 100 | 3.44 |
12:14 ET | 100 | 3.44 |
12:19 ET | 300 | 3.45 |
12:21 ET | 250 | 3.4496 |
12:26 ET | 120 | 3.44 |
12:28 ET | 100 | 3.44 |
12:30 ET | 100 | 3.44 |
12:33 ET | 200 | 3.46 |
12:35 ET | 100 | 3.45 |
12:37 ET | 3420 | 3.4101 |
12:44 ET | 100 | 3.435 |
12:46 ET | 1000 | 3.4336 |
12:50 ET | 3100 | 3.46 |
12:55 ET | 400 | 3.46 |
12:57 ET | 100 | 3.46 |
01:00 ET | 200 | 3.4319 |
01:02 ET | 100 | 3.46 |
01:04 ET | 400 | 3.44 |
01:06 ET | 100 | 3.44 |
01:08 ET | 100 | 3.44 |
01:11 ET | 800 | 3.46 |
01:13 ET | 260 | 3.42 |
01:15 ET | 10800 | 3.43 |
01:20 ET | 300 | 3.425 |
01:27 ET | 100 | 3.44 |
01:29 ET | 5400 | 3.41 |
01:31 ET | 500 | 3.43 |
01:33 ET | 700 | 3.44 |
01:36 ET | 100 | 3.44 |
01:38 ET | 100 | 3.44 |
01:44 ET | 100 | 3.44 |
01:45 ET | 1100 | 3.44 |
01:47 ET | 105 | 3.44 |
01:51 ET | 3605 | 3.42 |
01:54 ET | 2900 | 3.41 |
01:56 ET | 100 | 3.41 |
01:58 ET | 100 | 3.41 |
02:00 ET | 4300 | 3.38 |
02:02 ET | 421 | 3.39 |
02:03 ET | 1269 | 3.36 |
02:07 ET | 5984 | 3.399 |
02:12 ET | 100 | 3.41 |
02:14 ET | 1312 | 3.42 |
02:16 ET | 600 | 3.4225 |
02:18 ET | 100 | 3.4225 |
02:23 ET | 100 | 3.45 |
02:25 ET | 1000 | 3.4275 |
02:27 ET | 200 | 3.45 |
02:30 ET | 100 | 3.425 |
02:32 ET | 607 | 3.42 |
02:38 ET | 3196 | 3.42 |
02:39 ET | 100 | 3.425 |
02:41 ET | 100 | 3.425 |
02:43 ET | 100 | 3.425 |
02:50 ET | 1290 | 3.4 |
02:52 ET | 500 | 3.4225 |
02:54 ET | 200 | 3.425 |
03:03 ET | 200 | 3.42 |
03:06 ET | 100 | 3.4225 |
03:10 ET | 4800 | 3.401 |
03:14 ET | 100 | 3.42 |
03:15 ET | 100 | 3.42 |
03:26 ET | 200 | 3.41 |
03:28 ET | 100 | 3.43 |
03:33 ET | 100 | 3.43 |
03:35 ET | 400 | 3.42 |
03:37 ET | 100 | 3.42 |
03:39 ET | 100 | 3.42 |
03:42 ET | 100 | 3.42 |
03:44 ET | 929 | 3.42 |
03:46 ET | 500 | 3.42 |
03:50 ET | 100 | 3.42 |
03:51 ET | 400 | 3.42 |
03:53 ET | 800 | 3.41 |
03:55 ET | 855 | 3.42 |
04:00 ET | 1594 | 3.42 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Capricor Therapeutics Inc | 102.8M | -3.0x | --- |
Nanopharmaceutics Inc | 105.8M | -181.0x | --- |
Shattuck Labs Inc | 101.5M | -1.1x | --- |
Reviva Pharmaceuticals Holdings, Inc. | 102.7M | -2.5x | --- |
BioXcel Therapeutics Inc | 104.5M | -0.5x | --- |
Kinnate Biopharma Inc | 102.7M | -0.8x | --- |
Capricor Therapeutics, Inc. is a biotechnology company. The Company is focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). CAP-1002 is designed to slow disease progression in DMD through the immunomodulatory, anti-inflammatory, and anti-fibrotic actions of cardiosphere-derived cells (CDCs), which are mediated by secreted exosomes laden with bioactive cargo. CAP-2003 is the name of its exosomes product candidate, which is derived from its CDCs. It is also developing its exosome technology as a therapeutic platform. The Company’s focus is on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA), as well as proteins to treat or prevent a variety of diseases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $102.8M |
---|---|
Revenue (TTM) | $14.0M |
Shares Outstanding | 30.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.84 |
EPS | $-1.15 |
Book Value | $0.47 |
P/E Ratio | -3.0x |
Price/Sales (TTM) | 7.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -219.67% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.